RNA antagonist compounds for the modulation of PIK3CA expression

Details for Australian Patent Application No. 2008333714 (hide)

Owner Enzon Pharmaceuticals, Inc. Santaris Pharma A/S

Inventors Hedt Jarn, Maj

Agent Griffith Hack

Pub. Number AU-A-2008333714

PCT Pub. Number WO2009/071082

Priority 60/992,050 03.12.07 US

Filing date 26 November 2008

Wipo publication date 11 June 2009

International Classifications

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

Event Publications

24 June 2010 PCT application entered the National Phase

  PCT publication WO2009/071082 Priority application(s): WO2009/071082

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008333718-Probiotic bacteria and regulation of fat storage

2008333700-Method for producing a security and/or valuable document with personalised information